Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
|Articles|December 31, 2013
Supplements and Featured Publications
- Castration-Resistant Prostate Cancer: Addressing Treatment Challenges, Managed Care Aspects, and Int
- Volume 19
- Issue 18 Suppl
Post Test: Castration-Resistant Prostate Cancer: Addressing Treatment Challenges, Managed Care Aspects, and Integration of Existing and New Therapies Into Practice
Advertisement
Instructions
After reading “Castration-Resistant Prostate Cancer: Addressing Treatment Challenges, Managed Care Aspects, and Integration of Existing and New Therapies Into Practice,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
almost 13 years ago
Managed Care Implications in Castration-Resistant Prostate Canceralmost 13 years ago
Challenges in Treating Advanced Diseasealmost 13 years ago
Current State of Castration-Resistant Prostate CancerAdvertisement
Related to this article
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5